Recently, Kossel Medtech (Suzhou) Co., Ltd. completed more than 100 million RMB of B-round financing. It was led by Fortune Capital, followed by SIDVC company, Suzhou new district Hi-tech Industrial and Medpark.
Expectations from Arrow Hu, CEO of Kossel Medtech (Suzhou) Co., Ltd.
2024 is the first year of the third five-year plan for Kossel Medtech (Suzhou) Co., Ltd., and the successful completion of this round of financing fully demonstrates the continued optimism of investors in Kossel Medtech (Suzhou) Co., Ltd. and their confidence in the company’s product positioning, competitiveness and prospects. It will help the company to deepen the vascular intervention platform and international layout, enrich the product pipeline, expand the production base, absorb more talents, and lay a solid foundation for the company to successfully achieve the goal of “becoming China’s leading and globally renowned innovative medical device enterprise in the field of vascular intervention”. Kossel people will always know the unity of action, do pragmatic hard work, learn the trend of the industry, achieve win-win cooperation with all parties, and create the industry ecology.
After ten years of development, Kossel Medtech (Suzhou) Co., Ltd. has completed the platform layout: The parent company Kossel Medtech (Suzhou) Co., Ltd.focuses on building a “one-stop” treatment system in the field of peripheral intervention such as Falspeed® PTA Balloon Dilatation Catheter, the subsidiary Suzhou Haiyu Medtech Co., Ltd. provides a comprehensive solution for tachycardia treatment, the subsidiary Mixin Medtech(Suzhou) Co., Ltd focuses on the development of products in the field of coronary intervention and the transformation of overseas products and technologies, and the subsidiary Haiwin Medtech (Suzhou) Co., Ltd. is committed to the research and development of core raw materials. Kossel Medtech (Suzhou) Co., Ltd. actively promoted the global strategy, and acquired Micell at the end of 2021, taking a solid step toward globalization.
Kossel Medtech (Suzhou) Co., Ltd. always adheres to the concept of “from the clinical, serving the clinical” and practices it, continues to invest in research, development, and lean manufacturing, creates excellent products for patients
